Media coverage about Flexion Therapeutics (NASDAQ:FLXN) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flexion Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 45.4607207656772 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several research firms have issued reports on FLXN. Royal Bank of Canada set a $44.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Sunday, October 29th. BMO Capital Markets reissued an “outperform” rating and set a $37.00 target price (up previously from $35.00) on shares of Flexion Therapeutics in a research note on Monday, October 9th. Needham & Company LLC raised their target price on Flexion Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. Northland Securities reissued a “buy” rating and set a $40.00 target price on shares of Flexion Therapeutics in a research note on Friday, November 10th. Finally, Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $106.25.
Shares of Flexion Therapeutics (NASDAQ FLXN) opened at $26.45 on Tuesday. Flexion Therapeutics has a one year low of $16.51 and a one year high of $32.25. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $992.96, a price-to-earnings ratio of -7.54 and a beta of 1.15.
In related news, insider Neil Bodick bought 2,700 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $24.49 per share, with a total value of $66,123.00. Following the purchase, the insider now directly owns 64,605 shares of the company’s stock, valued at approximately $1,582,176.45. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael D. Clayman bought 5,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the purchase, the insider now directly owns 35,395 shares in the company, valued at $835,322. The disclosure for this purchase can be found here. Insiders own 15.98% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first published by BBNS and is the property of of BBNS. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://baseballnewssource.com/markets/flexion-therapeutics-flxn-given-daily-media-sentiment-score-of-0-14/1838848.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.